08-Apr-2022

PARP Inhibitors Market is estimated to top US$ 5.51 Bn by 2022

Rising burden of various types of cancers such as ovarian, breast, prostate, and pancreatic cancer is anticipated to generate significant demand for PARP inhibitors. According to the Global Cancer Observatory (GLOBOCAN), countries such as China, the U.S., India, and Japan, collectively diagnose over 120,000 new cases of ovarian cancer each year.

For more insights into the market, request a sample of this report@ https://www.futuremarketinsights.com/reports/sample/rep-gb-3197

he incidence of breast cancer is much higher in these countries, and with superior efficacy of PARP inhibitors as compared to other available cancer treatment options, the PARP inhibitors market is expected to gain significant revenue over the forecast period.

The global PARP inhibitors market is estimated to be valued at US$ 8.43Bn by 2026, expanding at a significant CAGR from 2022 to 2026.

Key Takeaways of PARP Inhibitors Market Study

Olaparib, with various expanded approvals for the treatment of ovarian cancer, breast cancer, and pancreatic cancer, and rapid increase in potential patient pool, contributed to the dominance of the segment by drug in 2021, and will continue to do so during the forecast period.
PARP inhibitors are regarded as a new standard of care for ovarian cancer after first-line platinum chemotherapy. Adoption of PARP inhibitors for ovarian cancer treatment has surged, and the trend is expected to continue during the forecast period, owing to the ability of PARP inhibitors to induce ovarian cancer patients into remission for longer periods of time as compared to any other marketed therapy.
With a strong pipeline, significant number of PARP inhibitors are expected to go for approval through the new drug application (NDA) process and for expanded approval to treat various types of cancers.

Strategic Acquisitions & Collaborations by Key Players to Widen Regional Presence

All marketed PARP inhibitors are under patent, and with no generic launch in sight till 2027, the market is expected to remain consolidated till the second half of this decade. Key players in the PARP inhibitors market are undergoing major collaborative efforts, mergers, and acquisitions in order to expand their regional product offerings.

For critical insights on this market, request to ask an expert here @ https://www.futuremarketinsights.com/askus/rep-gb-3197

For example, in January 2022, GlaxoSmithKline plc acquired TESARO Inc., an oncology-focused biopharmaceutical company with a marketed PARP inhibitor named Zejula (Niraparib).

Contact Us
Unit No: 1602-006
Jumeirah Bay 2
Plot No: JLT-PH2-X2A
Jumeirah Lakes Towers
Dubai
United Arab Emirates
LinkedIn| Twitter| Blogs

Editor Details

Company:
- MARKITWIRED
Website:
- MARKITWIRED

Last Updated: 08-Apr-2022